Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium

Infect Dis Ther. 2019 Mar;8(1):1-3. doi: 10.1007/s40121-018-0222-1. Epub 2018 Nov 20.
No abstract available

Keywords: Cost-effectiveness analysis; Economic evaluation; Pneumococcal conjugate vaccine; Pneumococcal disease.

Publication types

  • Letter